USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...
Top-rated Caribbean medical school expands USMLE preparation with fully integrated UWorld access and enhanced academic support, reinforcing its commitment to student success
NEW YORK, July...
WOBURN, Mass., July 9, 2025 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription products, today announced that the...
NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...
New buildings opening, additional Westminster and Rock Creek investments announced
DENVER, July 8, 2025 /PRNewswire/ -- Kaiser Permanente is announcing a major expansion of its medical...
Netflix-style interface enhances the learning experience for Aesthetic Society and AlliedPro members—designed to advance education and support professional growth.
GARDEN GROVE, Calif., July 8, 2025...
Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.
Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.
New chief operating officer, chief quality officer added to core AHN c-suite team led by recently appointed president Mark Sevco
PITTSBURGH, July 8, 2025 /PRNewswire/...
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...